RxDoctor Payments Data

John Vlattas, MD

Pain Medicine · Bayside, NYNPI 1063414852

Payments from drug & device makers

$3,587in general payments, 2019–2025

Across 89 payments — averaging $40.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$1K
  • Boston Scientific$699
  • Scilex Pharmaceuticals Inc.$639
  • Nevro Corp.$256
  • ERMI LLC$146
  • Collegium Pharmaceutical, Inc.$76
  • plus $394 from 12 others

What the payments were for

  • Travel & lodging$93726%
  • Food & beverage$2,62973%
  • Education$211%
  • Gifts$00%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,587 in reported general payments places this provider in the 65th percentile of 503 pain medicine providers in New York.

See all pain medicine providers in New York

Medicare billing

Part B allowed, 2024
$17,875
Medicare patients
79
Services billed
326

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SymproicNaldemedine Tosylate12$5,461
Oxycodone Hcl270$5,334
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen255$4,079
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen169$2,713
Pregabalin73$2,031
Gabapentin240$1,895
Naloxone Hcl27$1,783
Morphine Sulfate ErMorphine Sulfate61$1,187
Morphine Sulfate25$999
Cyclobenzaprine Hcl133$799
Tramadol Hcl106$753
Diclofenac Sodium24$696
Celecoxib54$620
Tizanidine Hcl81$503
Acetaminophen-CodeineAcetaminophen With Codeine59$382

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Shionogi IncSymproic$14$5,46112 claims
Hikma Pharmaceuticals USAMorphine Sulfate$21$99925 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 503 pain medicine providers in New York.

Other pain medicine in Bayside

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →